Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Escitalopram

Cipralex, Entact e altri

Bibliografia - Quali fonti bibliografiche per Escitalopram?

  1. Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.

  2. Alexopoulos G.S. et al., 42nd Annual meeting of the American College of Neuropsychopharmacology, 2003.

  3. Alisky J.M., Singapore Medical J., 2006, 47, 1014.

  4. Alwan S. et al., NEJM, 2007, 356, 2684.

  5. Angermann C.E. et al., JAMA, 2016, 315 (24), 2683.

  6. Bergeron L. et al., Ann. Pharmacother., 2005, 39, 956.

  7. Bielski R.J. et al., 16th Congress of the European College of Neuropsychopharmacology, 2003.

  8. Burke W.J. et al., J. Clin. Psychiatry, 2002, 63, 331.

  9. Casper R.C. et al., J. Pediatr., 2003, 142, 402.

  10. Chambers C.D. et al., NEJM, 2006, 354, 579.

  11. Chris C., Australian Prescriber 2006, 29, 71.

  12. Clayton A. et al., J. Sex Med., 2007, 4 (4 Pt 1), 917.

  13. Colonna L. e al., 3rd Int. Forum on Mood and Anxiety Disorder, 2002.

  14. Colonna L. et al., Curr. Med. Res. Opin., 2005, 21 (10), 1659.

  15. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.

  16. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.

  17. Food and Drug Administration – FDA, Lexapro – Label information, 2014 https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory (accesso: luglio 2016)

  18. Gorman J.M. et al., CNS Spectrum 2002, 7 (Suppl. 1), 40.

  19. Gulseren L. et al., Arch. Med. Res., 2005, 36 (2), 159.

  20. Gutierrez M.M. et al., Clin. Ther., 2003, 25 (4), 1200.

  21. Hayes B.D. et al., J. Emerg. Med., 2008.

  22. Jureidini J.N. et al., BMJ, 2004, 328, 879.

  23. Kirby D. et al., Internet J. Ger. Psychiatry, 2002, 17, 231.

  24. Kurdyak P.A. et al., J. Clin. Psychopharmacol., 2005, 25, 561.

  25. Lane RM. SSRI induced extrapyramidal side effects and akathisia: implication for treatment. J Psychopharmacol 1998; 12: 192-214.

  26. Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.

  27. Lancet, 2009, 373, 746.

  28. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.

  29. Lepola U.M. et al., Int. Clin. psychopharmacol., 2003, 18 (4), 211.

  30. Louik C. et al., NEJM, 2007, 356, 2675.

  31. Luìz-Lazaro PM, Cuevas Esteban J., European Neuropsychopharmacology 2007; 17 (suppl.4): 573.

  32. Malm H. et al., Obstet. Gynecol., 2005, 106, 1289.

  33. Mezuk B. et al., Osteoporos. 2007.

  34. Mills J.L., NEJM, 2006, 354, 636.

  35. Montgomery S.A. et al., Pharmacol. Toxicol., 2001, 88, 282.

  36. Montgomery S.A. et al., 44th Annual Meeting of the Scandinavian College of Neuropsychopharmacology, 2003.

  37. Moore N. et al., Int. Clin. Psychopharmacol., 2005, 20 (3), 131.

  38. Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.

  39. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.

  40. Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.

  41. Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.

  42. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.

  43. Owens M.J. et al., Biol. Psychiatry, 2001, 50 (5), 345.

  44. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.

  45. Rao N., Clin. Pharmacokinet., 2007, 46 (4), 281.

  46. Rapaport M.H. et al., J. Clin. Psychiatry, 2004, 65 (1), 44.

  47. Sanchez C. et al., Behav Pharmacol., 2003, 75, 903.

  48. Sansone R.A., Sansone L.A., Int. J. Psychiatry Med., 2003, 33 (1), 103.

  49. Serebruany V.L., Am. J. Med., 2006, 119, 113.

  50. Spigset O., Adielsson G., Int. Clin. Psychopharmacol., 1997, 12, 61.

  51. Stahl S.M. et al., J. Clin. Psychiatry, 2003, 64 (11), 1322.

  52. Steinacher L. et al., Eur. Neuropsychopharmacol., 2002, 12 (3), 255.

  53. von Moltke L.L. et al., Drug Metab. Dispos., 2001, 29, 1102.

  54. van Walraven C. et al., BMJ, 2001, 323, 655.

  55. Wade A. et al., Int. Clin. Psychopharmacol., 2002, 17 (3), 95.

  56. Wagner K.D. et al., JAMA, 2003, 290, 1033.

  57. Waugh J., Goa K.L., CNS Drugs, 2003, 17 (5), 343.

  58. Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.

  59. Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.